Bernhard Schlevogt
YOU?
Author Swipe
View article: Comparative analysis of SEC61A1 mutant R236C in two patient-derived cellular platforms
Comparative analysis of SEC61A1 mutant R236C in two patient-derived cellular platforms Open
SEC61A1 encodes a central protein of the mammalian translocon and dysfunction results in severe disease. Recently, mutation R236C was identified in patients having autosomal dominant polycystic liver disease (ADPLD). The molecular phenotyp…
View article: Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis—A real-world case series
Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis—A real-world case series Open
Background and Aims: Chronic hepatitis D is the most debilitating form of viral hepatitis frequently progressing to cirrhosis and subsequent decompensation. However, the HDV entry inhibitor bulevirtide is only approved for antiviral treatm…
View article: Enhanced monitoring and detection of recent genotype 3 hepatitis E virus infection through urine antigen testing
Enhanced monitoring and detection of recent genotype 3 hepatitis E virus infection through urine antigen testing Open
Hepatitis E virus (HEV) is the leading cause of acute viral hepatitis. Numerous studies have investigated the dynamics of HEV infection markers, but the most suitable marker for diagnosing ongoing or recent HEV infection remains to be dete…
View article: A Novel Insertion in the Hepatitis B Virus Surface Protein Leading to Hyperglycosylation Causes Diagnostic and Immune Escape
A Novel Insertion in the Hepatitis B Virus Surface Protein Leading to Hyperglycosylation Causes Diagnostic and Immune Escape Open
Chronic hepatitis B virus (HBV) infection is a global health threat. Mutations in the surface antigen of HBV (HBsAg) may alter its antigenicity, infectivity, and transmissibility. A patient positive for HBV DNA and detectable but low-level…
View article: A <i>SEC61A1</i> variant is associated with autosomal dominant polycystic liver disease
A <i>SEC61A1</i> variant is associated with autosomal dominant polycystic liver disease Open
Background and Aims Autosomal dominant polycystic liver and kidney disease is a spectrum of hereditary diseases, which display disturbed function of primary cilia leading to cyst formation. In autosomal dominant polycystic kidney disease a…
View article: Management of Hepatic Sarcoidosis
Management of Hepatic Sarcoidosis Open
Background and Aims: Liver involvement in sarcoidosis may occur in up to 60% of all patients. As many patients experience only minor symptoms, a high number of undiagnosed cases must be assumed. In order to successfully identify patients w…
View article: Secondary Sclerosing Cholangitis Following Coronavirus Disease 2019 (COVID-19): A Multicenter Retrospective Study
Secondary Sclerosing Cholangitis Following Coronavirus Disease 2019 (COVID-19): A Multicenter Retrospective Study Open
Background Secondary sclerosing cholangitis (SSC) is a rare disease with poor prognosis. Cases of SSC have been reported following coronavirus disease 2019 (COVID-SSC). The aim of this study was to compare COVID-SSC to SSC in critically il…
View article: Progressive liver, kidney, and heart degeneration in children and adults affected by TULP3 mutations
Progressive liver, kidney, and heart degeneration in children and adults affected by TULP3 mutations Open
Organ fibrosis is a shared endpoint of many diseases, yet underlying mechanisms are not well understood. Several pathways governed by the primary cilium, a sensory antenna present on most vertebrate cells, have been linked with fibrosis. C…
View article: Weight Gain after Interferon-Free Treatment of Chronic Hepatitis C—Results from the German Hepatitis C-Registry (DHC-R)
Weight Gain after Interferon-Free Treatment of Chronic Hepatitis C—Results from the German Hepatitis C-Registry (DHC-R) Open
Chronic hepatitis C can be treated very effectively with direct-acting antivirals (DAA) with only minor side effects compared to an interferon-containing treatment regimen. The significance of metabolic comorbidities after HCV cure is not …
View article: Immune‐Mediated Hepatitis Induced by Therapy With Alemtuzumab in a Patient With Multiple Sclerosis
Immune‐Mediated Hepatitis Induced by Therapy With Alemtuzumab in a Patient With Multiple Sclerosis Open
Increased use of immunomodulatory agents has led to emerging forms of drug-induced liver injury. Alemtuzumab is a recombinant, humanized monoclonal antibody against CD52, which is present on T cells, B cells, monocytes, and natural killer …
View article: Letter: a 5‐year long‐term follow‐up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis
Letter: a 5‐year long‐term follow‐up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis Open
LINKED CONTENT This article is linked to Mecci et al paper. To view this article, visit https://doi.org/10.1111/apt.15296 .
View article: Chronic Hepatitis E Virus Infection during Lymphoplasmacytic Lymphoma and Ibrutinib Treatment
Chronic Hepatitis E Virus Infection during Lymphoplasmacytic Lymphoma and Ibrutinib Treatment Open
Hepatitis E virus (HEV) is an increasingly recognised pathogen, affecting several hundred thousand individuals in western countries each year. Importantly, the majority of immunocompromised individuals are not able to clear HEV but develop…
View article: HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection
HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection Open
Objective: HCV clearance by current antiviral therapies improves clinical outcomes but falls short in eliminating the risk for hepatocellular carcinoma (HCC) emergence. As the HCC immune surveillance establishment is vital for the control …
View article: Supplementary Material for: HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection
Supplementary Material for: HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection Open
Objective: HCV clearance by current antiviral therapies improves clinical outcomes but falls short in eliminating the risk for hepatocellular carcinoma (HCC) emergence. As the HCC immune surveillance establishment is vital for the control …
View article: Interferon‐free therapy of chronic hepatitis C with direct‐acting antivirals does not change the short‐term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis
Interferon‐free therapy of chronic hepatitis C with direct‐acting antivirals does not change the short‐term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis Open
Summary Background Hepatitis C virus ( HCV ) clearance with IFN ‐based therapies reduces the incidence of hepatocellular carcinoma ( HCC ). There has been some debate if IFN ‐free therapy with direct‐acting antivirals alters the risk for H…
View article: Letter: can persisting liver stiffness indicate increased risk of hepatocellular cell carcinoma after successful anti-HCV therapy? - authors’ reply
Letter: can persisting liver stiffness indicate increased risk of hepatocellular cell carcinoma after successful anti-HCV therapy? - authors’ reply Open
Sirs, We read with interest the letter by the group of Dr Wiegand describing their experience on the potential value of liver stiffness measurement in patients receiving interferon (IFN)-free therapies of hepatitis C.1 Indeed, the findings…